

Claims:

1. An anti-idiotypic antibody fused to albumin or a functional fragment of albumin.
2. The anti-idiotypic antibody albumin fusion according to claim 1, wherein the anti-idiotypic antibody is specific for an anti-CD38 antibody having a variable heavy domain comprising the amino acid sequence
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSTNTYYADSVKGRFTISRDN
SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAWVGQGLTVTVSS (SEQ ID NO: 7), and a variable light
chain domain comprising the amino acid sequence
DIELTQPPSVSVAPGQTARISCSGDNLRHYVYVYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGT
QAEDEADYYCQTYTGASLVFGGGKLTVLGQ (SEQ ID NO: 8).
3. The anti-idiotypic antibody albumin fusion according to any one of the preceding claims, wherein
said anti-idiotypic antibody comprises a variable heavy chain comprising
an HCDR1 of the amino acid sequence YSFSNYWIS (SEQ ID NO: 18),
an HCDR2 of the amino acid sequence WMGIIDPASSKTRYSPSFQG (SEQ ID NO: 19),
an HCDR3 of the amino acid sequence SRGAGMDY (SEQ ID NO: 20), and
a variable light chain comprising
an LCDR1 of the amino acid sequence TGSSSNIGAGYDVH (SEQ ID NO: 21),
an LCDR2 of the amino acid sequence LLIYADNNRPS (SEQ ID NO: 22),
an LCDR3 of the amino acid sequence GSYDESSNSM (SEQ ID NO: 23).
4. The anti-idiotypic antibody albumin fusion according to any one of the preceding claims, wherein
said anti-idiotypic antibody comprises the variable heavy chain of the amino acid sequence
QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWISWVRQMPGKGLEWMGIIDPASSKTRYSPSFQGGQVTISADKS
ISTAYLQWSSLKASDTAMYCARSRGAGMDYWGQGLTVTVSS (SEQ ID NO: 16), and the variable light
chain of the amino acid
sequenceDIVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYADNNRPSGVPDRFSGSK
SGTSASLAITGLQSEADYYCGSYDESSNSMVFGGKLTVLGQ (SEQ ID NO: 17).
5. The anti-idiotypic antibody albumin fusion according any one of the preceding claims, wherein the
heavy chain comprises the amino acid sequence
QVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWISWVRQMPGKGLEWMGIIDPASSKTRYSPSFQGGQVTISADKS

6. The anti-idiotypic antibody albumin fusion according any one of the preceding claims, wherein the light chain comprises the amino acid sequence
DIVLTQPPSVSGAPGQRVTISCTGSSSNIGAGYDVHWYQQLPGTAPKLLIYADNNRPSGVPDRFSGSKSGTSASLA
ITGLQSEDEADYYCGSYDESSNSMVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVA
WKADSSPVKAGVETTTPSKQSNKYAASSYLSLTPEQWKSHRYSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO:
25).
7. The anti-idiotypic antibody albumin fusion according any one of the preceding claims for use in
evaluating a blood sample.
8. A nucleic acid encoding the anti-idiotypic antibody albumin fusion according to any one of the
preceding claims.
9. A method of evaluating a blood sample obtained from a patient undergoing treatment for multiple
myeloma or other gammopathy comprising
 - a) obtaining a blood sample from said patient,
 - b) incubating the blood sample with an anti-idiotypic antibody albumin fusion according to any
one of claims 1-7,
 - c) performing immunofixation electrophoresis (IFE), and
 - d) reporting the results of the IFE,where the sample is evaluated for total M-protein levels.

10. A method according to claim 9, wherein the patient is undergoing treatment with the antibody having a variable heavy domain comprising the amino acid sequence
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDN
SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (SEQ ID NO: 7), and a variable light
chain domain comprising the amino acid
sequenceDIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGN
TATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO: 8).
11. An anti-idiotypic antibody that is specific for an anti-CD38 antibody having a variable heavy domain comprising the amino acid sequence
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDN
SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (SEQ ID NO: 7), and a variable light
chain domain comprising the amino acid
sequenceDIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGN
TATLTISGTQAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO: 8).
12. A method of evaluating a blood sample obtained from a patient undergoing treatment for multiple myeloma or other gammopathy comprising
- a) obtaining a blood sample from said patient,
 - b) incubating the blood sample with an anti-idiotypic antibody,
 - c) performing immunofixation electrophoresis (IFE), and
 - d) reporting the results of the IFE,
- wherein the patient is undergoing treatment with the anti-CD38 antibody having a variable heavy domain comprising the amino acid sequence
QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMNWVRQAPGKGLEWVSGISGDPSNTYYADSVKGRFTISRDN
SKNTLYLQMNSLRAEDTAVYYCARDLPLVYTGFAYWGQGTLVTVSS (SEQ ID NO: 7), and a variable light
chain domain comprising the amino acid sequence
DIELTQPPSVSVAPGQTARISCSGDNLRHYYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGT
QAEDEADYYCQTYTGGASLVFGGGTKLTVLGQ (SEQ ID NO: 8),
where the sample is evaluated for total M-protein levels.
13. The antibody according to claim 11 or method according to claim 12, wherein said anti-idiotypic antibody comprises a variable heavy chain comprising
an HCDR1 of the amino acid sequence YSFSNYWIS (SEQ ID NO: 18),

an HCDR2 of the amino acid sequence WMGIIDPASSKTRYSPSFQG (SEQ ID NO: 19),
an HCDR3 of the amino acid sequence SRGAGMDY (SEQ ID NO: 20), and
a variable light chain comprising
an LCDR1 of the amino acid sequence TGSSSNIGAGYDVH (SEQ ID NO: 21),
an LCDR2 of the amino acid sequence LLIYADNNRPS (SEQ ID NO: 22),
an LCDR3 of the amino acid sequence GSYDESSNSM (SEQ ID NO: 23).